8-K: Can B Corp Acquires Cannabis Liquid Formulation Patents Through Subsidiary

Can B Corp, through its subsidiary Nascent Pharma, has acquired patents for liquid cannabis formulations, including beverages and vape liquids, with potential applications for various medical conditions.

Summary

• Can B Corp, via its 67% owned subsidiary Nascent Pharma, has acquired composition of matter and use patents for liquid cannabis formulations.
• The patents cover various applications including beverages, tinctures, vape pen liquids, and liquid-filled capsules.
• These formulations are patented for managing conditions such as cancer, irritable bowel syndrome, chronic pain, PTSD, anxiety, sleep disorders, and opioid dependencies.
• An independent valuation in 2020 estimated the patents' value at $122 million, after applying a 90% discount and projecting revenue through August 2034.
• Nascent will distribute 5% of Can B Corp's share of its revenues to creditors of a prior patent owner, up to a total of $10 million.
• The inventor of the patents will receive 50% of distributions received by Can B Corp from Nascent under a consulting agreement.

Sentiment

Score: 7

Explanation: The acquisition of patents is a positive development, but the lack of guaranteed revenue and the obligations to creditors and the inventor temper the overall sentiment. The valuation is positive but discounted.

Positives

• The acquisition of patents for liquid cannabis formulations expands Can B Corp's intellectual property portfolio.
• The patents have potential applications in various medical conditions, opening up new market opportunities.
• The independent valuation of $122 million suggests significant potential value for the patents.
• The consulting agreement with the inventor could provide valuable expertise and support for development.

Negatives

• There is no assurance that the patents will generate revenue for the company.
• The actual value of the patents may not equal the $122 million valuation.
• Nascent is obligated to distribute 5% of Can B Corp's share of its revenues to creditors of a prior patent owner, up to a total of $10 million.
• The inventor of the patents will receive 50% of distributions received by Can B Corp from Nascent, reducing the company's potential profit.

Risks

• The patents may not generate the projected revenue streams.
• The actual value of the patents may be lower than the independent valuation.
• The company is dependent on Nascent's success in licensing and developing the patents.
• The company is obligated to make payments to creditors and the inventor, which could impact profitability.

Future Outlook

The company plans to pursue opportunities to license and develop uses for the acquired patents through its subsidiary, Nascent Pharma.

Management Comments

• Can B Corp. announced today that through its 67% owned subsidiary, Nascent Pharma, LLC (Nascent), it has acquired composition of matter and use patents.

Industry Context

This acquisition positions Can B Corp to capitalize on the growing market for cannabis-based therapeutics and products, particularly in liquid formulations. The company is entering a competitive space with other companies also developing cannabis-based products for medical and recreational use.

Comparison to Industry Standards

• The valuation of $122 million for the patents, while discounted, suggests a significant potential value, which is comparable to other intellectual property assets in the cannabis industry.
• The licensing and development strategy is a common approach in the pharmaceutical and biotech sectors, where companies often leverage patents to generate revenue.
• The 5% revenue share to creditors and 50% distribution to the inventor are typical arrangements in patent acquisitions and consulting agreements.

Stakeholder Impact

• Shareholders may benefit from the potential revenue generation and increased value of the company's intellectual property.
• Creditors of the prior patent owner will receive payments from Nascent's revenues.
• The inventor of the patents will receive a share of distributions from Nascent.

Next Steps

• Nascent Pharma will pursue opportunities to license and develop uses for the patents.
• The company will monitor the progress of Nascent and the potential revenue generation from the patents.

Key Dates

Keywords

cannabis, patents, liquid formulations, pharmaceutical, Nascent Pharma, intellectual property, licensing, medical conditions, beverages, vape liquids